Current leaders in the PEPTIC CUP standings are Grey Nuns Hospital and Red Deer Regional Hospital!

**Prismocitrate 18: Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)**

**PROTOCOL # 1407-004**
clinicaltrials.gov: NCT02860130

**Study Sponsor: Baxter Healthcare Corporation**  
**Principal Investigator: Dr. Sean Bagshaw and Dr. Noel Gibney**  
**Primary Research Coordinator: Nadia Baig**

**Study Design:** This study is a multi-center, prospective, non-blinded, one to one randomized study. A total of 160 adult patients, 80 in each study arm, will be enrolled at up to 15 investigational sites in the USA and Canada.

Patients meeting all of the inclusion criteria and none of the exclusion criteria of this protocol and deemed treatable by either CRRT with Prismocitrate 18 solution or CRRT with no systemic anticoagulation are eligible for enrollment in the study. If a patient is receiving standard-of-care CRRT, they must be randomized within 24 hours of initiation of their standard-of-care CRRT. All patients will be treated with continuous venovenous hemodiafiltration (CVVHDF) as the study CRRT modality.

Patients enrolled in the study will receive either Prismocitrate 18 anticoagulation or no systemic anticoagulation during their CRRT, and the extracorporeal circuit life will be monitored for up to 120 hours of study CRRT (Treatment Period). During the Treatment Period, the adequacy of anticoagulation in the Prismocitrate 18 patients will be assessed by monitoring extracorporeal circuit pressures and by assessment of systemic and post-filter blood iCa concentrations.

**Primary Objective:**
The purpose of this research is to determine if an investigational new drug solution called Prismocitrate 18 lengthens extracorporeal circuit life in patients treated with continuous renal replacement therapy (CRRT). Patients who receive CRRT treatment with Prismocitrate 18 as the anticoagulant will be compared to patients who receive CRRT treatment with no anticoagulation.

**STARRT-AKI trial awarded $1.55 million grant from the Fall 2017 CIHR Project**

Study Enrollment Update

- ALFSG = 60  
- ROTEM Sub-Study = pending  
- BALANCE = 26  
- PREVENT = 4  
- PROSPECT = 9  
- STARRT-AKI: GS-ICU = 23  
- CV-ICU = 2

All of our studies have had enrollments since the beginning of the New Year!